FDA warned telehealth seller Measured its website misbranded compounded semaglutide and tirzepatide by implying it made them and that they were FDA-approved.
What happened
FDA reviewed the company's website at trymeasured.com in December 2025 and found it offering compounded semaglutide and tirzepatide drug products. The product labels pictured on the site show the name "Measured," which suggests Measured is the compounder of those drugs when it is not. The site also said the products are made with "the same active ingredients" found in Wegovy, Ozempic, Zepbound and Mounjaro, which implies the compounded products were FDA-approved when they were not.
What FDA found
The website labels name Measured as the maker of drugs it does not compound, which is false and misleading labeling.
FDCA section 502(a) [21 U.S.C. § 352(a)]; 21 CFR § 201.1(h)(2)Advertising or promoting a compounded drug in a false or misleading way misbrands that drug.
FDCA section 502(bb) [21 U.S.C. § 352(bb)]Telling customers the products contain the same active ingredient as Wegovy, Ozempic, Zepbound and Mounjaro implies FDA approval or review that never happened.
FDCA sections 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]Sending these misbranded drugs across state lines is a prohibited act.
FDCA section 301(a) [21 U.S.C. § 331(a)]Receiving or delivering misbranded drugs in interstate commerce is also prohibited.
FDCA section 301(c) [21 U.S.C. § 331(c)]Compounded drugs must meet the conditions of section 503A or 503B to be excused from the new drug approval requirements.
FDCA sections 503A and 503B [21 U.S.C. §§ 353a, 353b]
What FDA wants
Within 15 working days, send a written response to FDA's Office of Compounding Quality and Compliance describing the steps taken to fix the violations and prevent them from recurring. That response should name the entities that actually produce the compounded products, include a sample of the product labeling, and explain or show removal of the other website claims that could be seen as false or misleading.
Who should pay attention
- telehealth companies selling compounded GLP-1 drugs
- compounding pharmacies that supply products sold under another company's brand
- marketers who put their own name on drug labels they do not manufacture
This is a summary. Read the original letter on fda.gov.